These findings suggest that the IRS1/Akt/GSK-3β/GLUT4 signaling pathway, at least partly, contributes the beneficial effect of ICS II on hepatic glycogenesis and insulin resistance in T2DM. The gene discussed is AKT1; the disease is Insulin resistance.